Changing Your Device Manufacturing Site Location? Read This US FDA Proposal
This article was originally published in SRA
The US Food and Drug Administration has issued a draft guidance to address submission and inspection requirements when a company moves where its device manufacturing activities take place, either within a single facility or to a completely new location, or to a contract manufacturer1. It's the latest effort by the FDA to clarify what has historically been a nebulous area for manufacturers: what steps to take when making a modification to an approved device.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.